↓ Skip to main content

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report

Overview of attention for article published in Frontiers in Psychiatry, June 2018
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
110 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
Published in
Frontiers in Psychiatry, June 2018
DOI 10.3389/fpsyt.2018.00260
Pubmed ID
Authors

Muneto Izuhara, Hiroyuki Matsuda, Ami Saito, Maiko Hayashida, Syoko Miura, Arata Oh-Nishi, Ilhamuddin Abdul Azis, Rostia Arianna Abdullah, Keiko Tsuchie, Tomoko Araki, Arauchi Ryousuke, Misako Kanayama, Sadayuki Hashioka, Rei Wake, Tsuyoshi Miyaoka, Jun Horiguchi

Abstract

The authors present the case of a 38-year-old man with schizophrenia and with severe insomnia, who attempted suicide twice during oral drug therapy with risperidone. The patient slept barely 2 or 3 h per night, and he frequently took half days off from work due to excessive daytime sleepiness. As a maladaptive behavior to insomnia, he progressively spent more time lying in bed without sleeping, and he repeatedly thought about his memories, which were reconstructed from his hallucinations. His relatives and friends frequently noticed that his memories were not correct. Consequently, the patient did not trust his memory, and he began to think that the hallucinations controlled his life. During his insomniac state, he did not take antipsychotic drugs regularly because of his irregular meal schedule due to his excessive daytime sleepiness. The authors started cognitive behavioral therapy for insomnia (CBT-i) with aripiprazole long acting injection (LAI). CBT-i is needed to be tailored to the patient's specific problems, as this case showed that the patient maladaptively use chlorpromazine as a painkiller, and he exercised in the middle of the night because he believed he can fall asleep soon after the exercise. During his CBT-i course, he learned how to evaluate and control his sleep. The patient, who originally wanted to be short sleeper, began to understand that adequate amounts of sleep would contribute to his quality of life. He finally stopped taking chlorpromazine and benzodiazepine as sleeping drugs while taking suvorexant 20 mg. Through CBT-i, he came to understand that poor sleep worsened his hallucinations, and consequently made his life miserable. He understood that good sleep eased his hallucinations, ameliorated his daytime sleepiness and improved his concentration during working hours. Thus, he was able to improve his self-esteem and self-efficacy by controlling his sleep. In this case report, the authors suggest that CBT-i can be an effective therapy for schizophrenia patients with insomnia to the same extent of other psychiatric and non-psychiatric patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 110 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 15%
Unspecified 14 13%
Student > Master 10 9%
Student > Doctoral Student 10 9%
Student > Ph. D. Student 9 8%
Other 15 14%
Unknown 36 33%
Readers by discipline Count As %
Psychology 23 21%
Unspecified 14 13%
Medicine and Dentistry 7 6%
Nursing and Health Professions 5 5%
Neuroscience 4 4%
Other 11 10%
Unknown 46 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2018.
All research outputs
#18,639,173
of 23,090,520 outputs
Outputs from Frontiers in Psychiatry
#6,993
of 10,211 outputs
Outputs of similar age
#253,548
of 328,349 outputs
Outputs of similar age from Frontiers in Psychiatry
#156
of 175 outputs
Altmetric has tracked 23,090,520 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,211 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,349 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 175 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.